Natsumi Ogawa

机构：ABB (Japan), AbbVie (Japan)

发表论文 7 篇 · 总被引 76 次 · h-index 4

代表论文

• Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses (2019 · Biochemical and Biophysical Research Communications · 被引 35)
• Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (2020 · International Journal of Hematology · 被引 20)
• Trimebutine attenuates high mobility group box 1–receptor for advanced glycation end-products inflammatory signaling pathways (2020 · Biochemical and Biophysical Research Communications · 被引 11)
• Trimebutine suppresses Toll-like receptor 2/4/7/8/9 signaling pathways in macrophages (2021 · Archives of Biochemistry and Biophysics · 被引 9)
• Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax (2023 · International Journal of Hematology · 被引 1)
• A phase 2 study of ibrutinib with venetoclax in Japanese patients with untreated CLL and SLL (2025 · International Journal of Hematology)